Trials / Active Not Recruiting
Active Not RecruitingNCT05740202
A Trial of SHR-7367 in Subjects With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of SHR-7367 in Subjects With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-7367 in subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-7367 | The study was divided into three phases, the dose escalation phase and the dose extension phase and therapeutic effect extension of SHR-7367 in subjects with advanced malignant tumors. |
Timeline
- Start date
- 2023-03-06
- Primary completion
- 2025-11-30
- Completion
- 2025-11-30
- First posted
- 2023-02-22
- Last updated
- 2025-08-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05740202. Inclusion in this directory is not an endorsement.